PU-H71 effectively induces degradation of IκB kinase β in the presence of TNF-α

Molecular and Cellular Biochemistry

Volumn 386, Issue 1-2, 2014, Pages 135-142

  Qu, Zhuling ^a   Wang, Shiduan ^a   Teng, Ruyang ^a   Yi, Xuanlong ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

IKK ; NF B pathway; PU H71; TNF

Indexed keywords

ANTINEOPLASTIC AGENT; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PU H 71; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS ASSAY; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME DEGRADATION; IMMUNOBLOTTING; INTRACELLULAR SIGNALING; LUCIFERASE ASSAY; MTT ASSAY; TRANSCRIPTION TERMINATION; TUMOR CELL LINE;

APOPTOSIS; BASE SEQUENCE; BENZODIOXOLES; CELL LINE; CELL LINE, TUMOR; DNA PRIMERS; DOWN-REGULATION; HUMANS; I-KAPPA B KINASE; PROTEOLYSIS; PURINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84891526569     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1852-y     Document Type: Article

References (39)

1. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH (1997) Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90:65-75
2. da Silva VC, Ramos CH (2012) The network interaction of the human cytosolic 90 kDa heat shock protein Hsp90: a target for cancer therapeutics. J Proteomics 75:2790-2802
3. Taipale M, Jarosz DF, Lindquist S (2010) HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11:515-528
4. Theodoraki MA, Caplan AJ (2012) Quality control and fate determination of Hsp90 client proteins. Biochim Biophys Acta 1823:683-688
5. Holzbeierlein JM, Windsperger A, Vielhauer G (2010) Hsp90: a drug target? Curr Oncol Rep 12:95-101
6. Pacey S, Banerji U, Judson I, Workman P (2006) Hsp90 inhibitors in the clinic. Handb Exp Pharmacol 172:331-358
7. Neckers L, Ivy SP (2003) Heat shock protein 90. Curr Opin Oncol 15:419-424
8. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407-410
9. Wu Z, Moghaddas Gholami A, Kuster B (2012) Systematic identification of the HSP90 candidate regulated proteome. Mol Cell Proteomics 11:12
10. Usmani SZ, Bona RD, Chiosis G, Li Z (2010) The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1. J Hematol Oncol 3:40
11. Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, Varticovski L, Melnick A, Chiosis G (2009) Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci USA 106:8368-8373
12. Chan CT, Paulmurugan R, Gheysens OS, Kim J, Chiosis G, Gambhir SS (2008) Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects. Cancer Res 68:216-226
13. Aggarwal BB (2003) Signaling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3:745-756
14. Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Differ 10:45-65
15. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P (1998) The death domain kinase RIP mediates the TNF-induced NF-κB signal. Immunity 8:297-303
16. Ting AT, Pimentel-Muinos FX, Seed B (1996) RIP mediates tumor necrosis factor receptor 1 activation of NF-κB but not Fas/APO-1-initiated apoptosis. EMBO J 15:6189-6196
17. Zhang J, Winoto A (1996) A mouse Fas-associated protein with homology to the human Mort1/FADD protein is essential for Fas-induced apoptosis. Mol Cell Biol 16:2756-2763
18. Karin M, Yamamoto Y, Wang QM (2004) The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 3:17-26
19. Yang J, Lin Y, Guo Z, et al. (2001) The essential role of MEKK3 in TNF-induced NFκB activation. Nat Immunol 2:620-624
20. Wu MX, Ao Z, Prasad KV, Wu R, Schlossman SF (1998) IEX-1L, an apoptosis inhibitor involved in NF-κB-mediated cell survival. Science 281:998-1001
21. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS (1998) NFκB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281:1680-1683
22. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M (2005) Reactive oxygen species promote TNFa induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120:649-661
23. Broemer M, Krappmann D, Scheidereit C (2004) Requirement of Hsp90 activity for IκB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-κB activation. Oncogene 23:5378-5386
24. Lewis J, Devin A, Miller A, et al. (2000) Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-κB activation. J Biol Chem 275:10519-10526
25. Zuo J, Bi C, Fan Y, et al. (2013) Cellular and computational studies of proteasome inhibition and apoptosis induction in human cancer cells by amino acid Schiff base-copper complexes. J Inorg Biochem 118:83-93
26. Goetz MP, Toft D, Reid J, et al. (2005) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23:1078-1087
27. Chiosis G, Caldas Lopes E, Solit D (2006) Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. Curr Opin Investig Drugs 7:534-541
28. Fukumoto R, Kiang JG (2011) Geldanamycin analog 17-DMAG limits apoptosis in human peripheral blood cells by inhibition of p53 activation and its interaction with heat-shock protein 90 kDa after exposure to ionizing radiation. Radiat Res 176:333-345
29. Lancet JE, Gojo I, Burton M, Quinn M, Tighe SM, Kersey K, Zhong Z, Albitar MX, Bhalla K, Hannah AL, Baer MR (2010) Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 24:699-705
30. Jhaveri K, Miller K, Rosen L, Schneider B, Chap L, Hannah A, Zhong Z, Ma W, Hudis C, Modi S (2012) A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors. Clin Cancer Res 18:5090-5098
31. Palacios C, Martín-Pérez R, López-Pérez AI, Pandiella A, López-Rivas A (2010) Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin- induced apoptosis. Leuk Res 34:1533-1538
32. Zheng N, Zou P, Wang S, Sun D (2011) In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes. Drug Metab Dispos 39:627-635
33. Chiosis G (2006) Discovery and development of purine scaffold Hsp90 inhibitors. Curr Top Med Chem 6:1183-1191
34. Borkovich KA, Farrelly FW, Finkelstein DB, Taulien J, Lindquist S (1989) Hsp82 is an essential protein that is required in higher concentrations for growth of cells at higher temperatures. Mol Cell Biol 9:3919-3930
35. Akner G, Mossberg K, Sundqvist KG, Gustafsson JA, Wikstrom AC (1992) Evidence for reversible, non-microtubule and non-microfilament-dependent nuclear translocation of hsp90 after heat shock in human fibroblasts. Eur J Cell Biol 58:356-364
36. Biggiogera M, Tanguay RM, Marin R, Wu Y, Martin TE, Fakan S (1996) Localization of heat shock proteins in mouse male germ cells: an immunoelectron microscopical study. Exp Cell Res 229:77-85
37. Langer T, Rosmus S, Fasold H (2003) Intracellular localization of the 90 kDA heat shock protein (HSP90α) determined by expression of a EGFP-HSP90α-fusion protein in unstressed and heat stressed 3T3 cells. Cell Biol Int 27:47-52
38. Pratt WB, Toft DO (1997) Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18:306-360
39. Keane MM, Rubinstein Y, Cuello M, et al. (2000) Inhibition of NF-κB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Res Treat 64:211-219